Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $12.2 million.

  • Tarsus Pharmaceuticals' Share-based Compensation rose 6511.13% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year increase of 3441.33%. This contributed to the annual value of $27.8 million for FY2024, which is 4028.24% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Share-based Compensation is $12.2 million, which was up 6511.13% from $8.2 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Share-based Compensation peaked at $12.2 million during Q3 2025, and registered a low of $782000.0 during Q3 2021.
  • For the 5-year period, Tarsus Pharmaceuticals' Share-based Compensation averaged around $5.4 million, with its median value being $5.4 million (2023).
  • The largest annual percentage gain for Tarsus Pharmaceuticals' Share-based Compensation in the last 5 years was 13725000.0% (2021), contrasted with its biggest fall of 7338.33% (2021).
  • Over the past 5 years, Tarsus Pharmaceuticals' Share-based Compensation (Quarter) stood at $2.2 million in 2021, then surged by 68.47% to $3.7 million in 2022, then surged by 49.33% to $5.5 million in 2023, then soared by 35.04% to $7.4 million in 2024, then surged by 65.38% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $8.2 million for Q2 2025, and $6.9 million during Q1 2025.